Peter Brossart

Q: What Schools Are Affiliated With Peter Brossart

Peter Brossart is affiliated with the following schools: University of Tübingen, University of Genoa, University of Washington, University of Bonn

Peter Brossart's AcademicInfluence.com Rankings

Peter Brossart

Philosophy

#8897

World Rank

#12363

Historical Rank

Logic

#5908

World Rank

#7360

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Peter Brossart's Degrees

PhD Biomedical Sciences University of California, San Francisco
Doctorate Medicine Stanford University

Why Is Peter Brossart Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Peter Brossart's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Regression of human metastatic renal cell carcinoma after vaccination with tumor cell–dendritic cell hybrids (2000) (675)
Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells. (2000) (557)
The use of dendritic cells in cancer immunotherapy. (2008) (434)
Differential impact of allelic ratio and insertion site in FLT3-ITD-positive AML with respect to allogeneic transplantation. (2014) (343)
Presentation of exogenous protein antigens on major histocompatibility complex class I molecules by dendritic cells: pathway of presentation and regulation by cytokines. (1997) (340)
Identification of HLA-A2-restricted T-cell epitopes derived from the MUC1 tumor antigen for broadly applicable vaccine therapies. (1999) (339)
Virus-mediated delivery of antigenic epitopes into dendritic cells as a means to induce CTL. (1997) (296)
Survivin is a shared tumor-associated antigen expressed in a broad variety of malignancies and recognized by specific cytotoxic T cells. (2003) (281)
The JAK-inhibitor ruxolitinib impairs dendritic cell function in vitro and in vivo. (2013) (281)
Sorafenib, but not sunitinib, affects function of dendritic cells and induction of primary immune responses. (2008) (270)
Improved Outcomes With Retinoic Acid and Arsenic Trioxide Compared With Retinoic Acid and Chemotherapy in Non-High-Risk Acute Promyelocytic Leukemia: Final Results of the Randomized Italian-German APL0406 Trial. (2017) (265)
Her-2/neu-derived peptides are tumor-associated antigens expressed by human renal cell and colon carcinoma lines and are recognized by in vitro induced specific cytotoxic T lymphocytes. (1998) (253)
Immunologic and clinical responses after vaccinations with peptide-pulsed dendritic cells in metastatic renal cancer patients. (2006) (238)
Dendritic Cell Immunogenicity Is Regulated by Peroxisome Proliferator-Activated Receptor γ1 (2002) (231)
Proteasome inhibitors: antitumor effects and beyond (2007) (231)
The epithelial tumor antigen MUC1 is expressed in hematological malignancies and is recognized by MUC1-specific cytotoxic T-lymphocytes. (2001) (215)
Intradermal vaccinations with RNA coding for TAA generate CD8+ and CD4+ immune responses and induce clinical benefit in vaccinated patients. (2011) (197)
PPAR-gamma agonists inhibit toll-like receptor-mediated activation of dendritic cells via the MAP kinase and NF-kappaB pathways. (2004) (196)
RUNX1 mutations in acute myeloid leukemia are associated with distinct clinico-pathologic and genetic features (2016) (193)
Monocyte-derived dendritic cells are permissive to the complete replicative cycle of human cytomegalovirus. (2000) (193)
Signal-regulatory protein alpha (SIRPalpha) but not SIRPbeta is involved in T-cell activation, binds to CD47 with high affinity, and is expressed on immature CD34(+)CD38(-) hematopoietic cells. (2001) (190)
Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants (2017) (189)
Imatinib mesylate affects the development and function of dendritic cells generated from CD34+ peripheral blood progenitor cells. (2004) (181)
Processing and presentation of HLA class I and II epitopes by dendritic cells after transfection with in vitro-transcribed MUC1 RNA. (2005) (176)
Hematogenous spread of malignant melanoma cells in different stages of disease. (1993) (167)
Determinants of survival in patients with brain metastases from cutaneous melanoma (2010) (159)
JAK Inhibition Impairs NK Cell Function in Myeloproliferative Neoplasms. (2015) (155)
The Immune Checkpoint Regulator PD-L1 Is Highly Expressed in Aggressive Primary Prostate Cancer (2015) (150)
Ruxolitinib is a potent immunosuppressive compound: is it time for anti-infective prophylaxis? (2013) (149)
Bortezomib before and after high-dose therapy in myeloma: long-term results from the phase III HOVON-65/GMMG-HD4 trial (2018) (144)
CD63 tetraspanin slows down cell migration and translocates to the endosomal-lysosomal-MIICs route after extracellular stimuli in human immature dendritic cells. (2004) (141)
Nivolumab Alone and With Ipilimumab in Previously Treated Metastatic Urothelial Carcinoma: CheckMate 032 Nivolumab 1 mg/kg Plus Ipilimumab 3 mg/kg Expansion Cohort Results. (2019) (139)
Histone Deacetylase Inhibitors Affect Dendritic Cell Differentiation and Immunogenicity (2007) (138)
Tumor necrosis factor alpha and CD40 ligand antagonize the inhibitory effects of interleukin 10 on T-cell stimulatory capacity of dendritic cells. (2000) (136)
Dendritic cells in cancer vaccines. (2001) (135)
Proteasome inhibitor bortezomib modulates TLR4-induced dendritic cell activation. (2006) (132)
Platelets Recruit Human Dendritic Cells Via Mac-1/JAM-C Interaction and Modulate Dendritic Cell Function In Vitro (2007) (131)
A polymerase chain reaction-based semiquantitative assessment of malignant melanoma cells in peripheral blood. (1995) (131)
Evidence for a protective role of Mcl-1 in proteasome inhibitor-induced apoptosis. (2005) (128)
JAK1/2 inhibition impairs T cell function in vitro and in patients with myeloproliferative neoplasms (2015) (127)
Expression of MUC-1 epitopes on normal bone marrow: implications for the detection of micrometastatic tumor cells. (1999) (126)
Generation of functional human dendritic cells from adherent peripheral blood monocytes by CD40 ligation in the absence of granulocyte-macrophage colony-stimulating factor. (1998) (122)
Dectin-1 Interaction with Tetraspanin CD37 Inhibits IL-6 Production1 (2007) (117)
Delivery of tumor-derived RNA for the induction of cytotoxic T-lymphocytes (2003) (117)
Induction of myeloma-specific cytotoxic T cells using dendritic cells transfected with tumor-derived RNA. (2003) (117)
Rituximab consolidation after high-dose chemotherapy and autologous blood stem cell transplantation in follicular and mantle cell lymphoma: a prospective, multicenter phase II study. (2004) (116)
Cyclin-dependent kinase inhibitor Dinaciclib (SCH727965) inhibits pancreatic cancer growth and progression in murine xenograft models (2011) (112)
G-quadruplexes: a promising target for cancer therapy (2021) (111)
Selective activation of Fas/Fas ligand-mediated cytotoxicity by a self peptide (1996) (107)
Cancer immunoediting by GITR (glucocorticoid‐induced TNF‐related protein) ligand in humans: NK cell/tumor cell interactions (2007) (104)
TLR ligands differentially affect uptake and presentation of cellular antigens. (2007) (100)
Epidemiological, genetic, and clinical characterization by age of newly diagnosed acute myeloid leukemia based on an academic population-based registry study (AMLSG BiO) (2017) (98)
Molecular and functional characterization of human Dectin-1. (2002) (98)
Transfection of Dendritic Cells with RNA Induces CD4- and CD8-Mediated T Cell Immunity Against Breast Carcinomas and Reveals the Immunodominance of Presented T Cell Epitopes1 (2003) (98)
Nivolumab in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: Efficacy and Safety in CheckMate 141 by Prior Cetuximab Use (2019) (95)
Overall survival and fungal infection-related mortality in patients with invasive fungal infection and neutropenia after myelosuppressive chemotherapy in a tertiary care centre from 1995 to 2006 (2010) (95)
Effects of Imatinib on Normal Hematopoiesis and Immune Activation (2005) (94)
Towards new horizons: characterization, classification and implications of the tumour antigenic repertoire (2020) (92)
Ex vivo generation of human cytomegalovirus‐specific cytotoxic T cells by peptide‐pulsed dendritic cells (2001) (89)
Generation of Functional Human Dendritic Cells From Adherent Peripheral Blood Monocytes by CD40 Ligation in the Absence of Granulocyte-Macrophage Colony-Stimulating Factor (1998) (88)
Effects of Imatinib on Monocyte-Derived Dendritic Cells Are Mediated by Inhibition of Nuclear Factor-κB and Akt Signaling Pathways (2005) (87)
The heat shock protein Gp96 binds to human neutrophils and monocytes and stimulates effector functions. (2003) (86)
hDectin-1 is involved in uptake and cross-presentation of cellular antigens. (2008) (83)
Induction of chronic lymphocytic leukemia (CLL)-specific CD4- and CD8-mediated T-cell responses using RNA-transfected dendritic cells. (2004) (82)
Proteasome inhibitor‐induced apoptosis in human monocyte‐derived dendritic cells (2006) (81)
Induction of Adipophilin-Specific Cytotoxic T Lymphocytes Using a Novel HLA-A2-Binding Peptide That Mediates Tumor Cell Lysis (2004) (78)
MicroRNA-146a reduces MHC-II expression via targeting JAK/STAT-signaling in dendritic cells after stem cell transplantation (2017) (76)
Human cytomegalovirus induces a direct inhibitory effect on antigen presentation by monocyte‐derived immature dendritic cells (2002) (76)
Idiotype vaccination of multiple myeloma patients using monocyte-derived dendritic cells. (2003) (76)
Impact of salvage regimens on response and overall survival in acute myeloid leukemia with induction failure (2017) (76)
Dendritic cell-based cancer immunotherapy targeting MUC-1 (2005) (75)
ASXL1 mutations in younger adult patients with acute myeloid leukemia: a study by the German-Austrian Acute Myeloid Leukemia Study Group (2015) (73)
Novel treatment concepts for graft-versus-host disease. (2012) (72)
Direct identification of major histocompatibility complex class I-bound tumor-associated peptide antigens of a renal carcinoma cell line by a novel mass spectrometric method. (1998) (72)
Matrilysin (MMP-7) Is a Novel Broadly Expressed Tumor Antigen Recognized by Antigen-Specific T Cells (2008) (68)
Cyclopentenone Prostaglandins Induce Lymphocyte Apoptosis by Activating the Mitochondrial Apoptosis Pathway Independent of External Death Receptor Signaling 1 (2003) (67)
Valproic acid in combination with all-trans retinoic acid and intensive therapy for acute myeloid leukemia in older patients. (2014) (66)
Diffusion-Weighted Magnetic Resonance Imaging of the Pancreas: Diagnostic Benefit From an Intravoxel Incoherent Motion Model–Based 3 b-Value Analysis (2014) (66)
Role of peroxisome proliferator-activated receptor gamma and its ligands in the control of immune responses. (2003) (65)
Hippo Signaling Mediates Proliferation, Invasiveness, and Metastatic Potential of Clear Cell Renal Cell Carcinoma1 (2014) (64)
Immunotherapy with dendritic cells for cancer. (2008) (64)
Immunomodulatory effects of anti-angiogenic drugs (2011) (64)
Detection of Residual Tumor Cells in Patients with Malignant Melanoma Responding to Immunotherapy (1994) (64)
Pan-Cancer Analysis of the Mediator Complex Transcriptome Identifies CDK19 and CDK8 as Therapeutic Targets in Advanced Prostate Cancer (2016) (63)
Cooperative Cytotoxicity of Proteasome Inhibitors and Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand in Chemoresistant Bcl-2-Overexpressing Cells (2005) (62)
Comprehensive Evaluation of Prostate Specific Membrane Antigen Expression in the Vasculature of Renal Tumors: Implications for Imaging Studies and Prognostic Role (2018) (61)
Dendritic cells in vaccination therapies of malignant diseases. (2002) (61)
The Role of Antigen Spreading in the Efficacy of Immunotherapies (2020) (61)
Clinical and immunological effects of mRNA vaccines in malignant diseases (2021) (58)
BCR-ABL activity is critical for the immunogenicity of chronic myelogenous leukemia cells. (2006) (57)
Cotransfection of dendritic cells with RNA coding for HER-2/neu and 4-1BBL increases the induction of tumor antigen specific cytotoxic T lymphocytes (2005) (57)
Identification and Characterization of T-Cell Epitopes Deduced from RGS5, a Novel Broadly Expressed Tumor Antigen (2007) (57)
Cellular Immunotherapy with Dendritic Cells in Cancer: Current Status (2004) (57)
All-trans retinoic acid as adjunct to intensive treatment in younger adult patients with acute myeloid leukemia: results of the randomized AMLSG 07-04 study (2016) (54)
Reduced immune effector cell NKG2D expression and increased levels of soluble NKG2D ligands in multiple myeloma may not be causally linked (2010) (53)
Neutralization of tumor-derived soluble glucocorticoid-induced TNFR-related protein ligand increases NK cell anti-tumor reactivity. (2008) (53)
The Tübingen approach: identification, selection and validation of tumor-associated HLA peptides for cancer therapy (2004) (52)
RNA Vaccines in Cancer Treatment (2010) (50)
Safety of multiple repeated cycles of 177Lu-octreotate in patients with recurrent neuroendocrine tumour (2017) (49)
Signal-regulatory protein a ( SIRP a ) but not SIRP b is involved in T-cell activation , binds to CD 47 with high affinity , and is expressed on immature CD 34 1 CD 38 2 hematopoietic cells (2001) (49)
IL‐4‐mediated fine tuning of IL‐12p70 production by human DC (2008) (48)
Treatment with lenalidomide induces immunoactivating and counter‐regulatory immunosuppressive changes in myeloma patients (2014) (48)
PD-L1: a novel prognostic biomarker in head and neck squamous cell carcinoma. (2017) (47)
The Role of Adding Somatostatin Analogues to Peptide Receptor Radionuclide Therapy as a Combination and Maintenance Therapy (2018) (47)
A phase I/II study of bortezomib and capecitabine in patients with metastatic breast cancer previously treated with taxanes and/or anthracyclines. (2008) (47)
The EMT transcription factor Zeb2 controls adult murine hematopoietic differentiation by regulating cytokine signaling. (2017) (46)
Single versus tandem high‐dose melphalan followed by autologous blood stem cell transplantation in multiple myeloma: long‐term results from the phase III GMMG‐HD2 trial (2016) (46)
Dendritic cells transfected with tumor RNA for the induction of antitumor CTL in colorectal cancer (2003) (45)
New developments in dendritic cell–based vaccinations: RNA translated into clinics (2005) (45)
PD-L1 (CD274) and PD-L2 (PDCD1LG2) promoter methylation is associated with HPV infection and transcriptional repression in head and neck squamous cell carcinomas (2017) (45)
Cyclopentenone prostaglandins induce caspase activation and apoptosis in dendritic cells by a PPAR-gamma-independent mechanism: regulation by inflammatory and T cell-derived stimuli. (2002) (45)
Development of Hemolytic Anemia in a Nivolumab-Treated Patient with Refractory Metastatic Squamous Cell Skin Cancer and Chronic Lymphatic Leukemia (2016) (45)
Dendritic cells in vaccination therapies of human malignant disease. (2004) (44)
Identification of a Lysosomal Peptide Transport System Induced during Dendritic Cell Development* (2007) (44)
Impact of pretreatment characteristics and salvage strategy on outcome in patients with relapsed acute myeloid leukemia (2017) (44)
Detection of a new JAK2 D620E mutation in addition to V617F in a patient with polycythemia vera (2006) (43)
The immune inhibitory receptor osteoactivin is upregulated in monocyte-derived dendritic cells by BCR–ABL tyrosine kinase inhibitors (2012) (42)
Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Cooperates with Anticancer Drugs to Overcome Chemoresistance in Antiapoptotic Bcl-2 Family Members Expressing Jurkat Cells (2004) (41)
Identification of C-Met Oncogene as a Broadly Expressed Tumor-Associated Antigen Recognized by Cytotoxic T-Lymphocytes (2004) (41)
PD-L1: a novel prognostic biomarker in head and neck squamous cell carcinoma (2017) (39)
Immune regulatory loops determine productive interactions within human T lymphocyte-dendritic cell clusters. (1999) (39)
JAK inhibitor ruxolitinib inhibits the expression of cytokines characteristic of cutaneous lupus erythematosus (2017) (39)
Midostaurin in Combination with Intensive Induction and As Single Agent Maintenance Therapy after Consolidation Therapy with Allogeneic Hematopoietic Stem Cell Transplantation or High-Dose Cytarabine (NCT01477606) (2015) (38)
Long-term results of all-trans retinoic acid and arsenic trioxide in non-high-risk acute promyelocytic leukemia: update of the APL0406 Italian-German randomized trial (2019) (38)
The induction of human myeloid derived suppressor cells through hepatic stellate cells is dose-dependently inhibited by the tyrosine kinase inhibitors nilotinib, dasatinib and sorafenib, but not sunitinib (2016) (38)
Family Mismatched Allogeneic Stem Cell Transplantation for Myelofibrosis: Report from the Chronic Malignancies Working Party of European Society for Blood and Marrow Transplantation. (2019) (37)
Antibiotic resistant bacteria and resistance genes in biofilms in clinical wastewater networks. (2019) (37)
Generation and functional characterization of MDSC-like cells (2017) (37)
Bortezomib Induction and Maintenance in Patients with Newly Diagnosed Multiple Myeloma: Long-Term Follow-up of the HOVON-65/GMMG-HD4 Trial (2015) (37)
Zoledronic acid inhibits the function of Toll-like receptor 4 ligand activated monocyte-derived dendritic cells (2007) (37)
Peptide Receptor Radionuclide Therapy Combined With Chemotherapy in Patients With Neuroendocrine Tumors (2019) (37)
Ectopic overexpression of Sonic Hedgehog (Shh) induces stromal expansion and metaplasia in the adult murine pancreas. (2011) (36)
Response-adapted lenalidomide maintenance in newly diagnosed myeloma: results from the phase III GMMG-MM5 trial (2020) (36)
Post-transcriptional regulation of adapter molecules by IL-10 inhibits TLR-mediated activation of antigen-presenting cells (2009) (35)
Expression of her-2/neu on acute lymphoblastic leukemias: implications for the development of immunotherapeutic approaches. (2003) (35)
Condensed versus standard schedule of high-dose cytarabine consolidation therapy with pegfilgrastim growth factor support in acute myeloid leukemia (2016) (35)
A liposomal formulation of the synthetic curcumin analog EF24 (Lipo-EF24) inhibits pancreatic cancer progression: towards future combination therapies (2016) (35)
Clinical Studies Applying Cytokine-Induced Killer Cells for the Treatment of Renal Cell Carcinoma (2012) (34)
BCR-ABL is not an immunodominant antigen in chronic myelogenous leukemia. (2006) (34)
Activation of Invariant NK T Cells in Periodontitis Lesions (2013) (33)
The JAK inhibitor ruxolitinib impairs dendritic cell migration via off-target inhibition of ROCK (2015) (33)
Clinical impact of GATA2 mutations in acute myeloid leukemia patients harboring CEBPA mutations: a study of the AML study group (2016) (32)
Implication of the Receptor Tyrosine Kinase AXL in Head and Neck Cancer Progression (2016) (32)
Nivolumab versus investigator’s choice in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: Efficacy and safety in CheckMate 141 by age (2019) (32)
Long-term survival correlates with immunological responses in renal cell carcinoma patients treated with mRNA-based immunotherapy (2015) (32)
Anticancer vaccination strategies. (2004) (31)
Molecular and immune correlates of TIM-3 (HAVCR2) and galectin 9 (LGALS9) mRNA expression and DNA methylation in melanoma (2019) (30)
Fatal outcome of human coronavirus NL63 infection despite successful viral elimination by IFN‐alpha in a patient with newly diagnosed ALL (2016) (30)
The occurrence of antimicrobial substances in toilet, sink and shower drainpipes of clinical units: A neglected source of antibiotic residues. (2019) (30)
ASXL 1 mutations in younger adult patients with acute myeloid leukemia : a study by the German-Austrian Acute Myeloid Leukemia Study Group (2015) (29)
Regulation of dectin-1-mediated dendritic cell activation by peroxisome proliferator-activated receptor-gamma ligand troglitazone. (2011) (29)
Vaccination strategies in patients with renal cell carcinoma (2009) (29)
Targeting DDR2 in head and neck squamous cell carcinoma with dasatinib (2016) (28)
Approaches to Dendritic Cell‐Based Immunotherapy after Peripheral Blood Stem Cell Transplantation (1999) (28)
The VEGF-Receptor Inhibitor Axitinib Impairs Dendritic Cell Phenotype and Function (2015) (28)
Salvage autologous transplant and lenalidomide maintenance vs. lenalidomide/dexamethasone for relapsed multiple myeloma: the randomized GMMG phase III trial ReLApsE (2020) (27)
Transfection of dendritic cells with in vitro-transcribed CMV RNA induces polyclonal CD8+- and CD4+-mediated CMV-specific T cell responses. (2006) (27)
The proteasome and its inhibitors in immune regulation and immune disorders. (2006) (27)
RUNX1 mutations in acute myeloid leukemia are associated with distinct clinico-pathologic and genetic features (2016) (26)
Parameters predicting COVID-19-induced myocardial injury and mortality☆ (2020) (26)
Nivolumab (Nivo) vs investigator’s choice (IC) in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): Efficacy and safety in CheckMate 141 by prior cetuximab use. (2017) (26)
Variable resistance to freezing and thawing of CD34-positive stem cells and lymphocyte subpopulations in leukapheresis products. (2016) (26)
MA09.05 Nivolumab Alone or with Ipilimumab in Recurrent Small Cell Lung Cancer (SCLC): 2-Year Survival and Updated Analyses from the Checkmate 032 Trial (2017) (25)
High-risk additional chromosomal abnormalities at low blast counts herald death by CML (2020) (25)
Analysis of the anti-proliferative and the pro-apoptotic efficacy of Syk inhibition in multiple myeloma (2015) (25)
Preexisting and Post–COVID-19 Immune Responses to SARS-CoV-2 in Patients with Cancer (2021) (24)
Molecular, clinicopathological, and immune correlates of LAG3 promoter DNA methylation in melanoma (2020) (24)
Generation of antigen-specific CTL responses using RGS1 mRNA transfected dendritic cells (2008) (24)
Inactivation of Brca2 cooperates with Trp53R172H to induce invasive pancreatic ductal adenocarcinomas in mice (2011) (24)
RNA transfection of dendritic cells. (2005) (24)
Impact of Age and Midostaurin-Dose on Response and Outcome in Acute Myeloid Leukemia with FLT3-ITD: Interim-Analyses of the AMLSG 16-10 Trial (2016) (23)
Induction of iodide uptake in transformed thyrocytes: a compound screening in cell lines (2009) (23)
In vivo and In vitro Identification of Endocannabinoid Signaling in Periodontal Tissues and Their Potential Role in Local Pathophysiology (2017) (23)
Intermediate intensity conditioning regimen containing FLAMSA, treosulfan, cyclophosphamide, and ATG for allogeneic stem cell transplantation in elderly patients with relapsed or high-risk acute myeloid leukemia (2011) (23)
Prognostic and predictive value of PD-L2 DNA methylation and mRNA expression in melanoma (2020) (23)
Inhibition of Six1 affects tumour invasion and the expression of cancer stem cell markers in pancreatic cancer (2017) (22)
The value of tumor markers in men with metastatic prostate cancer undergoing [177Lu]Lu‐PSMA therapy (2019) (22)
Induction of Minor Histocompatibility Antigen HA-1–Specific Cytotoxic T Cells for the Treatment of Leukemia After Allogeneic Stem Cell Transplantation (1999) (22)
Epithelial-specific transcription factor ESE-3 is involved in the development of monocyte-derived DCs. (2006) (22)
Role of Consolidation Therapy in the Treatment of Patients up to 60 Years with High Risk AML. (2005) (22)
Targeting myeloid derived suppressor cells with all-trans retinoic acid is highly time-dependent in therapeutic tumor vaccination (2017) (20)
Activated CD8+ T lymphocytes induce differentiation of monocytes to dendritic cells and restore the stimulatory capacity of interleukin 10-treated antigen-presenting cells. (2002) (19)
Cyclin-Dependent Kinase 5 (CDK5) Controls Melanoma Cell Motility, Invasiveness, and Metastatic Spread—Identification of a Promising Novel therapeutic target1 (2015) (19)
Advances in immunotherapy of chronic myeloid leukemia CML. (2013) (19)
Acquired perforating collagenosis in Hodgkin's disease. (2005) (19)
Agents targeting the Hedgehog pathway for pancreatic cancer treatment. (2010) (18)
MERTK as a novel therapeutic target in head and neck cancer (2016) (18)
Imatinib dose reduction in major molecular response of chronic myeloid leukemia: results from the German Chronic Myeloid Leukemia-Study IV (2018) (18)
Dendritic Cell‐Based Vaccines in Patients with Hematological Malignancies (2001) (18)
Lenalidomide Enhances MOR202 Dependent Macrophage-Mediated Effector Functions Via the Vitamin D Pathway (2015) (18)
T-cell receptor beta variable region diversity in melanoma metastases after interleukin 2-based immunotherapy. (1996) (18)
Successful Treatment of Refractory Squamous Cell Cancer of the Head and Neck with Nivolumab and Ipilimumab (2018) (17)
Successful treatment of refractory leiomyosarcoma with the PD-1 inhibitor nivolumab. (2016) (17)
Cyclopentenone prostaglandins induce caspase activation and apoptosis in dendritic cells by a PPAR-γ-independent mechanism (2002) (16)
Importance of whole-body imaging with complete coverage of hands and feet in alveolar rhabdomyosarcoma staging (2018) (16)
Response-Adapted Lenalidomide Maintenance in Newly Diagnosed, Transplant-Eligible Multiple Myeloma: Results from the Multicenter Phase III GMMG-MM5 Trial (2017) (16)
Recent developments of transgenic and xenograft mouse models of pancreatic cancer for translational research (2011) (15)
Retraction: Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids (2003) (15)
Implementing combinatorial immunotherapeutic regimens against cancer (2014) (15)
Current status of vaccination therapy for leukemias. (2005) (15)
The role of checkpoint blockade after allogeneic stem cell transplantation in diseases other than Hodgkin’s Lymphoma (2019) (15)
Effect of Tyrosine Kinase Inhibition Using Imatinib on Normal Lymphohematopoietic Cells (2005) (14)
Peripheral neuropathy associated with subcutaneous or intravenous bortezomib in patients with newly diagnosed myeloma treated within the GMMG MM5 phase III trial (2016) (14)
Proteasome inhibition overcomes the resistance of renal cell carcinoma cells against the PPARγ ligand troglitazone (2009) (13)
Lenalidomide versus bortezomib maintenance after frontline autologous stem cell transplantation for multiple myeloma (2021) (13)
T follicular helper cells: linking cancer immunotherapy and immune-related adverse events (2021) (13)
Salvage Autologous Transplant and Lenalidomide Maintenance Versus Continuous Lenalidomide/Dexamethasone for Relapsed Multiple Myeloma: Results of the Randomized GMMG Phase III Multicenter Trial Relapse (2018) (13)
Tigecycline in febrile neutropenic patients with haematological malignancies: a retrospective case documentation in four university hospitals (2014) (13)
Dendritic cells in clinical trials for multiple myeloma. (2005) (13)
Interleukin-2-based immunotherapy and chemoimmunotherapy in metastatic melanoma. (1995) (13)
Increase of In Vivo Antitumoral Activity by CD40L (CD154) Gene Transfer Into Pancreatic Tumor Cell-Dendritic Cell Hybrids (2009) (13)
Antitumor effects of arsenic trioxide in transformed human thyroid cells. (2008) (12)
CTLA4 promoter methylation predicts response and progression-free survival in stage IV melanoma treated with anti-CTLA-4 immunotherapy (ipilimumab) (2020) (12)
Interferon gamma modulates sensitivity of CML cells to tyrosine kinase inhibitors (2016) (12)
Inactivation of BRCA2 cooperates with Trp53R172H to induce invasive pancreatic ductal adenocarcinomas in mice: A mouse model of familial pancreatic cancer. (2011) (12)
Dexamethasone induced inhibition of Dectin-1 activation of antigen presenting cells is mediated via STAT-3 and NF-κB signaling pathways (2017) (11)
Characterization of BAX inhibitor-1 as a novel leukemia-associated antigen (2009) (11)
Subgroup Analyses of the Randomized GMMG Phase III Multicenter Trial Relapse Suggest Survival Benefit of Salvage Autologous Transplant Primarily in Low Risk Multiple Myeloma (2018) (11)
Serum Cytokine Levels in Cancer Patients Treated with Different Schedules of Ultra‐Low-Dose Interleukin‐2 (1994) (10)
Direct effects of protirelin (TRH) on cultured porcine thyrocytes (1992) (10)
Immunomodulatory effects of ultra-low-dose interleukin-2 in cancer patients: a phase-IB study (1993) (10)
Murine hematopoietic stem cell reconstitution potential is maintained by osteopontin during aging (2018) (10)
Nivolumab (N) alone or in combination with ipilimumab (I) in patients (pts) with platinum-pretreated metastatic urothelial carcinoma (mUC), including the nivolumab 1mg/kg + ipilimumab 3mg/kg expansion from CheckMate 032. (2018) (10)
Prevalence, therapy and tumour response in patients with rheumatic immune-related adverse events following immune checkpoint inhibitor therapy: a single-centre analysis (2021) (10)
The JAK1/JAK2 Inhibitor Ruxolitinib Substantially Affects NK Cell Biology (2013) (9)
Treatment response monitoring in patients with advanced malignancies using cell-free SHOX2 and SEPT9 DNA methylation in blood: An observational prospective study. (2020) (9)
AML versus ICU: outcome of septic AML patients in an intensive care setting (2015) (9)
Effects of Retinoids on Porcine Thyrocytes under Different Culture Conditions (2001) (9)
Intravesical cidofovir application in BK virus cystitis after allogeneic hematopoetic stem cell transplantation (HSCT) is safe and highly effective (2018) (9)
Nivolumab (nivo) vs investigator’s choice (IC) in patients (pts) with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): Analysis of CheckMate 141 by age. (2018) (8)
Sorafenib but not sunitinib affects the induction of immune responses (2007) (8)
Current Therapeutic Options for Pancreatic Ductal Adenocarcinoma (2018) (8)
Induction of minor histocompatiblity antigen HA-1-specific cytotoxic T cells for the treatment of leukemia after allogeneic stem cell transplantation. (1999) (8)
Weekly carboplatin in combination with weekly paclitaxel in the treatment of metastatic non-small cell lung cancer: a single center 10-year experience (2016) (8)
Outcome of empirical or targeted antifungal therapy after antifungal prophylaxis in febrile neutropenia (2016) (7)
Successful treatment of acute promyelocytic leukemia in pregnancy with single-agent all-trans retinoic acid (2018) (7)
C reactive protein flare predicts response to checkpoint inhibitor treatment in non-small cell lung cancer (2022) (7)
Fecal microbiota transfer for refractory intestinal graft‐versus‐host disease — Experience from two German tertiary centers (2021) (7)
Pharmacokinetics and pharmacodynamics of sunitinib for the treatment of advanced pancreatic neuroendocrine tumors (2013) (7)
Addition of dacarbazine or cisplatin to interferon‐α/interleukin‐2 in metastatic melanoma: toxicity and immunological effects (1995) (7)
γ-Glutamyl Transferase Is an Independent Biomarker of Splanchnic Thrombosis in Patients With Myeloproliferative Neoplasm (2016) (7)
Immune Checkpoint Imaging in Oncology: A Game Changer Toward Personalized Immunotherapy? (2020) (6)
Mixed Response to Ipilimumab in a Melanoma Patient with Brain Metastases: Case Report and Review of the Literature (2013) (6)
Conception and Feasibility of a Digital Tele-Guided Abdomen, Thorax, and Thyroid Gland Ultrasound Course for Medical Students (TELUS study) (2021) (6)
Restriction of T cell receptor V beta repertoire in melanoma metastasis responding to immunotherapy. (1995) (6)
Bortezomib-based induction, high-dose melphalan and lenalidomide maintenance in myeloma up to 70 years of age (2020) (6)
Vaccinations with RNA coding for tumor associated antigens in advanced RCC patients—A phase I/II study (2008) (6)
A matched-pair analysis on survival and response rates between German and non-German cancer patients treated at a Comprehensive Cancer Center (2019) (6)
Everolimus for the treatment of pancreatic neuroendocrine tumors (2012) (6)
A phase I dose-escalation and expansion study of intratumoral CV8102 as single-agent or in combination with anti-PD-1 antibodies in patients with advanced solid tumors. (2020) (6)
Tumor rejection in Cblb−/− mice depends on IL-9 and Th9 cells (2021) (6)
DC-based immunotherapy of B-cell malignancies. (2004) (5)
Imatinib mesylate and nilotinib affect MHC-class I presentation by modulating the proteasomal processing of antigenic peptides (2009) (5)
Knowledge transfer to enhance the performance of deep learning models for automated classification of B cell neoplasms (2021) (5)
Simultaneous Deletion of p21Cip1/Waf1 and Caspase-3 Accelerates Proliferation and Partially Rescues the Differentiation Defects of Caspase-3 Deficient Hematopoietic Stem Cells (2014) (5)
Regression of liver metastases after treatment with oxaliplatin/capecitabine and development of a progressive multifocal leukoencephalopathy in a patient with advanced thymoma. (2013) (5)
BIOLUMA: A phase II trial of nivolumab in combination with ipilimumab to evaluate efficacy and safety in lung cancer and to evaluate biomarkers predictive for response—Preliminary results from the SCLC cohort. (2019) (5)
Comparison of antibiotic prophylaxis with cotrimoxazole/colistin (COT/COL) versus ciprofloxacin (CIP) in patients with acute myeloid leukemia (2015) (5)
Development of novel compounds to treat autoimmune and inflammatory diseases and graft versus host reactions. (2007) (4)
Long Term Remission and Cardiac Toxicity of a Combination of Ipilimumab and Nivolumab in a Patient With Metastatic Head and Neck Carcinoma After Progression Following Nivolumab Monotherapy (2019) (4)
749P Nivolumab (N) alone or in combination with ipilimumab (I) in patients (pts) with platinum-pretreated metastatic urothelial carcinoma (mUC): Extended follow-up from CheckMate 032 (2020) (4)
BG-flow, a new flow cytometry tool for G-quadruplex quantification in fixed cells (2021) (4)
Specialized dermatological-rheumatological patient management improves diagnostic outcome and patient journey in psoriasis and psoriatic arthritis: a four-year analysis (2021) (4)
Phase I trial of bortezomib and capecitabine in patients with metastatic breast cancer previously treated with taxanes and/or anthracyclines (2005) (4)
A phase 1, open-label, multicenter, non-randomized study to assess the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of AZD4573, a potent and selective CDK9 inhibitor, in subjects with relapsed or refractory hematological malignancies. (2018) (4)
Selective BET-bromodomain inhibition by JQ1 suppresses dendritic cell maturation and antigen-specific T-cell responses (2020) (4)
First Line and Second Line Chemotherapy in Advanced Cholangiocarcinoma and Impact of Dose Reduction of Chemotherapy: A Retrospective Analysis (2021) (4)
Phase I trial of metastatic renal cell carcinoma with oral capecitabine and thalidomide (2009) (4)
Bortezomib-based induction therapy with high or low-dose dexamethasone in newly diagnosed, transplant-eligible multiple myeloma (2018) (4)
Autoantibodies to dense-fine-speckled 70 (DFS70) do not necessarily rule out connective tissue diseases (2021) (3)
Safety Performance of Healthcare Professionals: Validation and Use of the Adapted Workplace Health and Safety Instrument (2021) (3)
CD33 Delineates Two Functionally Distinct NK Cell Populations Divergent in Cytokine Production and Antibody-Mediated Cellular Cytotoxicity (2022) (3)
Prognostic Impact of Serum Free Light Chain Ratio Normalization in Patients with Multiple Myeloma Treated within the GMMG-MM5 Trial (2021) (3)
Severe Impairment of Dendritic Cell Allostimulatory Activity by Sendai Virus Vectors Is Overcome by Matrix Protein Gene Deletion. (2005) (3)
Helios-expressing CD8+ T cells are decreased in patients with systemic lupus erythematosus (2021) (3)
Crosspresentation: a matter of pH. (2008) (3)
EF24 Suppresses Cholangiocellular Carcinoma Progression, Inhibits STAT3 Phosphorylation, and Induces Apoptosis via ROS-Mediated Oxidative Stress (2019) (3)
Severe Impairment of Dendritic Cell Allostimulatory Activity by Sendai Virus Vectors Is Overcome by Matrix Protein Gene Deletion1 (2005) (3)
CD4+ T Cell Functions Are Potently Suppressed By The Janus Kinase 1/2 (JAK1/JAK2) Inhibitor Ruxolitinib (2013) (3)
The PI3Kδ inhibitor idelalisib impairs the function of human dendritic cells (2021) (3)
OP0318 THE ROLE OF DUAL ENERGY COMPUTED TOMOGRAPHY (DECT) IN THE DIFFERENTIATION OF GOUT AND CALCIUM PYROPHOSPHATE DEPOSITION DISEASE (2020) (3)
Exanthem subitum (human herpesvirus‐6 reactivation) after autologous stem cell transplantation (2016) (3)
Transient and fully reversible leukocytosis in a myelodysplastic syndrome patient upon initiation of azacitidine treatment (2013) (3)
The role of dual energy computed tomography in the differentiation of acute gout flares and acute calcium pyrophosphate crystal arthritis (2021) (3)
Bortezomib-Based Induction and Maintenance Overcomes the Negative Prognostic Impact of Renal Impairment and del17p in Transplant-Eligible Myeloma Patients: Long Term Results from the Phase III HOVON-65/GMMG-HD4 Study after Median 137 Months Follow up (2019) (3)
Dexamethasone Promotes Fungal Infection By Inhibition of APC Activation with Beta-Glucans Via STAT-3 and NF-κb (2016) (3)
MHC class I presentation of exogenous protein antigens by dendritic cells (1997) (3)
Development of Skin Rash Predicts Outcome of Anti-PD-1- and Anti-CTLA4-Based Immune Checkpoint Inhibitor Therapy in Non-Small Cell Lung Cancer or Squamous Cell Carcinoma of the Head and Neck: A Single-Center Analysis (2021) (3)
Dendritic Cells in Cancer: Current Status (2004) (2)
Modern approaches in studying T cell-mediated functional activity. (2003) (2)
CD40L-transfected myeloma cells transfer prolonged immunity in vivo. (2010) (2)
Molecular and immune correlates of TIM-3 (HAVCR2) and galectin 9 (LGALS9) mRNA expression and DNA methylation in melanoma (2019) (2)
Long-term follow-up of subcutaneous versus intravenous bortezomib during induction therapy for newly diagnosed multiple myeloma treated within the GMMG-MM5 Phase III Trial (2021) (2)
Total marrow irradiation versus total body irradiation using intensity-modulated helical tomotherapy (2023) (2)
Re-Educating Myeloma Associated Macrophages with Lenalidomide (2014) (2)
ASSESSMENT OF IMATINIB 400MG AS FIRST LINE TREATMENT OF CHRONIC MYELOID LEUKEMIA: 10-YEAR SURVIVAL RESULTS OF THE RANDOMIZED CML STUDY IV (2017) (2)
Systemic Therapy of Neuroendocrine Neoplasia: Single Center Experience from a Cohort of 110 Consecutive Cases (2020) (2)
FRI0548 PREVALENCE AND THERAPY OF RHEUMATOLOGICAL ADVERSE EVENTS DUE TO IMMUNE CHECKPOINT INHIBITOR THERAPY (2020) (2)
Clinical Risk Factors for Peripheral Neuropathy in Patients Treated with Subcutaneous or Intravenous Bortezomib for Newly Diagnosed Multiple Myeloma (2015) (2)
Blastic plasmacytoid dendritic-cell neoplasia: a challenging case report (2021) (2)
No evidence to support the impact of migration background on treatment response rates and cancer survival: a retrospective matched-pair analysis in Germany (2021) (2)
Pacritinib protects dendritic cells more efficiently than ruxolitinib. (2021) (2)
New Perspectives in Dendritic Cell-Based Cancer Immunotherapy (2012) (2)
Prevalence of joint, entheseal, tendon, and bursal findings in young, healthy individuals by musculoskeletal ultrasound (2021) (2)
Induction of clinical and immunological responses in patients with metastatic renal cell carcinoma after vaccinations with peptide pulsed dendritic cells (2005) (2)
Ruxolitinib Inhibits Dendritic Cell Function By Interfering With The MAP-Kinase/NF-Kb Signalling Pathways (2013) (2)
Correction: High-risk additional chromosomal abnormalities at low blast counts herald death by CML (2020) (2)
Intercellular cGAMP transmission induces innate immune activation and tissue inflammation in Trex1 deficiency (2021) (2)
Red blood cell transfusions impact response rates to immunotherapy in patients with solid malignant tumors (2022) (2)
Zeb2 loss in adult mice results in a myeloproliferative disorder and is associated with altered JAK/STAT signaling pathway (2015) (2)
in vivo The JAK-inhibitor ruxolitinib impairs dendritic cell function in vitro and (2013) (2)
Neutralization of Tumor-Derived Soluble Glucocorticoid-Induced TNF-Related Protein (GITR) Ligand Present in Cancer Patient Sera Increases Anti-Tumor Reactivity of NK Cells. (2007) (2)
Long‐term follow‐up of Cladribine, high‐dose Cytarabine, and Idarubicin as salvage treatment for relapsed acute myeloid leukemia and literature review (2020) (2)
Peripheral blood kinetics following total body irradiation and allogeneic hematopoietic stem cell transplantation: Timing matters (2022) (2)
Matrilysin (MMP-7) Is a Novel Broadly Expressed Tumor Antigen Recognized by Antigen-Specific T Cells. (2007) (2)
Her-2 / neu-derived Peptides Are Tumor-associated Antigens Expressed by Human Renal Cell and Colon Carcinoma Lines and Are Recognized by in Vitro Induced Specific Cytotoxic T Lymphocytes 1 (2006) (1)
Preexisting and post-COVID-19 immune responses to SARS-CoV-2 in cancer patients. (2021) (1)
Prevalence and characteristics of giant cell arteritis in patients with newly diagnosed polymyalgia rheumatica – a prospective cohort study (2023) (1)
Elotuzumab spares dendritic cell integrity and functionality (2021) (1)
Direct Assessment of IgA and IgG Paraprotein By Hevylite Assay and Correlation to IMWG Response and Progression-Free Survival in Newly Diagnosed, Transplant-Eligible Multiple Myeloma Patients in the Prospective Phase III GMMG-MM5 Trial (2017) (1)
Platelet-Dependent Thrombin Generation Induced By ADP or Activated Factor X Does Not Contribute to Increased In Vivo Thrombin Formation in Myeloproliferative Neoplasms (2018) (1)
Efficacy and tolerability of fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) in unselected patients with advanced gastric and gastroesophageal cancer: does age really matter? (2022) (1)
Immunotherapy in renal cell carcinoma. (2009) (1)
The JAK Inhibitor Ruxolitinib Substantially Affects NK Cells in MPN Patients (2014) (1)
Successful management of Candida krusei monoarthritis after allo-SCT (2013) (1)
Cancer care in German centers of excellence during the first 2 years of the COVID-19 pandemic (2022) (1)
Vemurafenib as bridging therapy of hairy cell leukemia in a Jehovah’s Witness patient (2021) (1)
Editorial: Versatile Roles for B Cells in Tumor Immunity (2022) (1)
Enhanced inhibition of tumor growth with depletion of CD25 regulatory cells and intratumoral immunization with tumor RNA-pulsed dendritic cells in a C57BL/6 pancreatic tumor model. (2009) (1)
Tumor‐derived soluble Glucocorticoid‐Induced TNF‐Related Protein (GITR) ligand diminishes anti‐tumor reactivity of NK cells (2008) (1)
Intradermal RNA-Vaccination of Patients with Metastatic Renal Cell Carcinoma. (2005) (1)
Antitumor immunity and T-cell avidity. (2020) (1)
Molecular Characterization of Relapsed Core-Binding Factor (CBF) Acute Myeloid Leukemia (AML) (2015) (1)
‘Diseases Desperate Grown by Desperate Appliance Are Relieved, or Not at all' - Towards Finding a Cure for Pancreatic Cancer, Where Do We Stand Today? (2018) (1)
Prospective Randomized Comparison of High Dose AraC and Autologous Peripheral Blood Stem Cell Transplantation as Late Consolidation for Patients ≤60 Years with Standard Risk AML. (2005) (1)
[Survey of physicians on dealing with the topic "Tobacco consumption in patients with lung cancer"]. (2018) (1)
OP0147 MEASUREMENT OF FLOW VELOCITIES OF THE CENTRAL RETINAL ARTERY IN PATIENTS WITH GIANT CELL ARTERITIS WITH VISUAL SYMPTOMS AND CONTROLS (2020) (1)
Epitope spreading occurs in cancer patients after vaccination with a single tumor antigen (2000) (1)
Her-2/neu-derived Peptides Are Tumor-associated Antigens Expressed by Human Renal Cell and Colon Carcinoma Lines and Are Recognized by in Vitro Induced Specific Cytotoxic T Lymphocytes1 (2006) (1)
Zoledronic Acid Inhibits the Function of Toll-Like Receptor 4 Ligand Activated Dendritic Cells. (2006) (1)
Comparison of bortezomib versus lenalidomide maintenance therapy in newly-diagnosed, transplant-eligible multiple myeloma: Results from the phase III GMMG-HD4 and -MM5 trials (2019) (1)
Preliminary Report for the Development of a Multiparameter Protocol for the Identification of Sinusoidal Obstruction Syndrome including Abdominal Ultrasound before and after Allogeneic Stem Cell Transplantation (2022) (1)
800 A phase I dose escalation and expansion study of intratumorally administered CV8102 as a single-agent or in combination with anti-PD-1 antibodies in patients with advanced solid tumors (2020) (1)
SARS-CoV-2 PrEP complicates antibody testing after vaccination: a call for awareness (2022) (1)
BIOLUMA: A phase II trial of nivolumab in combination with ipilimumab to evaluate efficacy and safety in lung cancer and to evaluate biomarkers predictive for response—Preliminary results from the NSCLC cohort. (2019) (1)
A 78-year-old female with severe tongue pain: benefit of modern ultrasound (2021) (1)
OA15.05 BIOLUMA: A Phase II Trial of Nivolumab and Ipilimumab in Lung Cancer – Prospective Evaluation of TMB in SCLC Patients (2019) (1)
G-quadruplexes: a promising target for cancer therapy (2021) (0)
RNAVaccines in Cancer Treatment (2014) (0)
Peptide to induce an immune response against tumor cells containing them pharmzeutische compositions, uses thereof, nucleic acid coding therefor and these nucleic acid expression vector containing (1999) (0)
Influence of insulin, proinsulin, IGF-I and TRH on the growth and iodide uptake of cultured porcine thyroid cells (1989) (0)
Prognostic Parameters in Melanoma for Response to Immunotherapy (1993) (0)
The potential of eHealth for cancer patients–does COVID-19 pandemic change the attitude towards use of telemedicine services? (2023) (0)
Development and implementation of a comprehensive ultrasound curriculum for medical students: The Bonn internship point-of-care-ultrasound curriculum (BI-POCUS) (2023) (0)
Nestin expression in osteocytes following myeloablation and during bone marrow metastasis (2022) (0)
This information is current as Signalingof External Death Receptor Mitochondrial Apoptosis Pathway Lymphocyte Apoptosis by Activating the Cyclopentenone Prostaglandins Induce (2013) (0)
Changes in ultrasound imaging of joints, entheses, bursae and tendons 24 and 48 h after adjusted weight training (2022) (0)
Clinical and immunological effects of mRNA vaccines in malignant diseases (2021) (0)
A party of three: iNKT cells in GVHD prevention. (2015) (0)
Pre-clinical and Early Clinical Experience Using Dendritic Cells to Treat Human Malignancy (1999) (0)
Addition of CDDP or DTIC to immunotherapy in melanoma (1993) (0)
1030PEvaluation of dose intensification of cytarabine in postremission therapy in older AML patients within the prospective phase II AMLSG 06-04 study (2017) (0)
Prediction of early overall and infection-related mortality during induction therapy in transplant-eligible multiple myeloma - a pooled analysis from three GMMG phase III trials (2017) (0)
Inhibition of Six1 affects tumour invasion and the expression of cancer stem cell markers in pancreatic cancer (2017) (0)
Antitumor effects of arsenic trioxide alone and in combination with pro-oxidants, Akt-inhibitors and sirolimus on transformed thyroid cells in vitro (2007) (0)
Zeb2-Defficiency in the Adult Murine Hematopoietic Precursor Cells Leads to Differentiation Defects in Multiple Hematopoietic Lineages and a Myeloproliferative-Like Phenotype (2012) (0)
γ-GT is associated with splanchnic thrombotic events, CRP predicts survival in patients with myeloproliferative neoplasms (2015) (0)
Perioperative Therapy with Flot4 Significantly Increases Survival in Patients with Gastroesophageal and Gastric Cancer in A Large Real-World Cohort. (2023) (0)
132PWEEKLY CARBOPLATIN AND PACLITAXEL IN ADVANCED NON-SMALL CELL LUNG CANCER: GOOD RESPONSE RATE BUT POOR OVERALL SURVIVAL IN A “REAL WORLD” POPULATION (2015) (0)
Publisher Correction: Bortezomib-based induction, high-dose melphalan and lenalidomide maintenance in myeloma up to 70 years of age (2021) (0)
Identification and Characterization of T-Cell Epitopes Deduced from RGS 5 , a Novel Broadly ExpressedTumorAntigen (2007) (0)
AB0846 CONCEPTION AND FEASIBILITY OF A DIGITAL TELE-GUIDED ABDOMEN, THORAX AND THYROID GLAND ULTRASOUND COURSE FOR MEDICAL STUDENTS (2021) (0)
Major Route Additional Chromosomal Aberrations (ACA) Precede Increase of Blasts in CML: An Analysis of the German CML-Studies III and IIIA (2015) (0)
A peptide antigen MUC-1 DNA corresponding to elicit an immune response against tumor cells (2000) (0)
Imatinib Inhibits Proteasomal Activity in CML Cells. (2007) (0)
A Polymerase Chain Reaction-based Semiquantitative Assessment of Malignant Melanoma Cells in Peripheral Blood 1 (2006) (0)
Interleukin-10 Severely Impairs TLR Mediated Activation of Antigen Presenting Cells. (2006) (0)
OP0151 AUTOANTIBODIES AGAINST DENSE-FINE-SPECKLED 70 (DFS70) DO NOT ENTIRELY EXCLUDE CONNECTIVE TISSUE DISEASES (2021) (0)
Whole body irradiation with intensity-modulated helical tomotherapy prior to haematopoietic stem cell transplantation: analysis of organs at risk by dose and its effect on blood kinetics. (2023) (0)
Human CD8+ Treg after Allogeneic Stem-Cell Transplantation (2016) (0)
Comparison of Empiric Antibiotic Escalation Therapy with Vancomycin (VAN) versus Linezolid (LIN) in Patients with Febrile Neutropenia (2022) (0)
Dexamethasone induced inhibition of Dectin-1 activation of antigen presenting cells is mediated via STAT-3 and NF-κB signaling pathways (2017) (0)
Postoperative adjuvant radiochemotherapy with cisplatin versus adjuvant radiochemotherapy with cisplatin and pembrolizumab in locally advanced head and neck squamous cell carcinoma- the study protocol of the Adrisk trial (2023) (0)
The E3 Ubiquitin Ligase Cbl-b Limits Nascent Th9 Differentiation (2015) (0)
On-treatment modified Glasgow prognostic score (mGPS) improves imaging-only prediction of response and outcomes in metastatic renal cell carcinoma (2023) (0)
Activated CD 8 T Lymphocytes Induce Differentiation of Monocytes to Dendritic Cells and Restore the Stimulatory Capacity of Interleukin 10-treated Antigen-presenting Cells 1 (2002) (0)
Prospective Phase III Trial Of Valproic Acid (VPA) In Combination With All-Trans Retinoic Acid (ATRA) and Intensive Induction Therapy For AML In Older Patients: Final and Molecular Subset Analyses Of The AMLSG 06-04 Study (2013) (0)
No evidence to support the impact of migration background on treatment response rates and cancer survival: a retrospective matched-pair analysis in Germany (2021) (0)
hDectin-1 Is Involved in the Uptake of Apoptotic and Infected Cells and Mediates Cross-Presentation of Engulfed Antigens. (2005) (0)
Ex Vivo Manipulation of Peripheral Blood CD34+ Cells (1998) (0)
Prospective double-blind study on the value of musculoskeletal ultrasound by dermatologists as a screening instrument for psoriatic arthritis. (2022) (0)
Treatment Results In Acute Myeloid Leukemia Over a Time Period Of 20 Years: Analysis Of The German-Austrian Acute Myeloid Leukemia Study Group (AMLSG) (2013) (0)
SAT0254 PROSPECTIVE ANALYSIS OF THE PREVALENCE OF GIANT CELL ARTERITIS IN CONSECUTIVE PATIENTS WITH POLYMYALGIA RHEUMATICA (2020) (0)
Deletion Vectors Is Overcome by Matrix Protein Gene Allostimulatory Activity by Sendai Virus Severe Impairment of Dendritic Cell (2005) (0)
Outcomes of Allogeneic Haematopoietic Stem Cell Transplantation for Therapy-Related Myeloid Neoplasms Following Treatment for Myeloma (2022) (0)
The Effects of Imatinib on the Function of Monocyte Derived Dendritic Cells Are Mediated Via the Inhibition of Akt and NF-kappaB Signal Transduction Pathways. (2004) (0)
Normalization of serum free light chains during therapy in the MM5 trial predicts prolonged progression free survival and overall survival (2019) (0)
707TiP Postoperative adjuvant radiochemotherapy (aRCH) with cisplatin versus aRCH with cisplatin and pembrolizumab in locally advanced head and neck squamous cell carcinoma: The ADRISK trial (2022) (0)
Therapeutic management and clinical remission for patients with psoriasis and psoriatic arthritis in a specialized dermatological‐rheumatological center (2022) (0)
Prediction of Early Death and Severe Infections during Novel Agent-Based Induction Therapy in Newly-Diagnosed Multiple Myeloma: An Intergroup Analysis from the German Speaking Myeloma Multicenter Group, the Dutch-Belgian Cooperative Trial Group for Hematology Oncology Foundation and the European Mye (2021) (0)
AB0847 ESTABLISHMENT AND VALIDATION OF A DIDACTIC MUSCULOSKELETAL ULTRASOUND COURSE FOR DERMATOLOGISTS USING AN INNOVATIVE HANDHELD ULTRASOUND SYSTEM – THE MUDE STUDY (MUSCULOSKELETAL ULTRASOUND IN DERMATOLOGY) (2021) (0)
Subject index for 1993 (1993) (0)
Birmingham Hippo signaling mediates proliferation, invasiveness, and metastatic potential of clear cell renal cell carcinoma (2014) (0)
PI3 Kinase Inhibition Induces Apoptotic Cell Death in Acute Lymphoblastic Leukemia Via the Mitochondrial Pathway. (2008) (0)
Immune Tolerance Induction and Immunosuppression in a 25-Year-Old Patient with Inherited Severe Factor IX Deficiency and Inhibitor: 1-Year Follow-Up (2022) (0)
Immunotherapy of malignant diseases with peptide pulsed dendritic cells (2001) (0)
Osteoactivin Mediates the Inhibitory Effects of Myeloid Derived Suppressor Cells (2014) (0)
The Potential of E-Health in Patients after Allogeneic Stem Cell Transplantation (2022) (0)
Immunity Against Breast Carcinomas and Induces CD4- and CD8-Mediated T Cell Transfection of Dendritic Cells with RNA (2003) (0)
Ruxolitinib-induced spleen size reduction predicts superior outcome after allogeneic stem cell transplantation in primary and post-PV/ET myelofibrosis - a study of the Cooperative German Transplant Study Group (KTS) (2016) (0)
Impact of Severe Infections during Induction Therapy on Dosage, Response and Survival in Newly Diagnosed Multiple Myeloma - a Subgroup Analysis from the Randomized Phase III Trial GMMG-HD4 (2015) (0)
Impact Of The Pretreatment Characteristics As Well As Cyto- and Molecular-Genetic Profile On Outcome After Relapse In Acute Myeloid Leukemia (2013) (0)
T-cell receptor repertoire in melanoma tissue and response to immunotherapy (1993) (0)
Primary Urethral Plasmacytoma Treated with High-Dose-Rate Brachytherapy: A Case Report (2016) (0)
BCR-ABL Is Not an Immunodominant Antigen in CML. (2005) (0)
Cost-Effectiveness Analysis of Arsenic Trioxide in Combination with All-Trans Retinoic Acid in Acute Promyelocytic Leukemia with Pretreatment White Blood Counts <10G/L (2014) (0)
Establishment and validation of a didactic musculoskeletal ultrasound course for dermatologists using an innovative handheld ultrasound system – the MUDE study (Musculoskeletal Ultrasound in Dermatology) (2021) (0)
The Current Situation of Musculoskeletal Ultrasound Education: A Systematic Literature Review. (2023) (0)
Identification and Characterization of T Cell Epitopes Deduced from RGS5, a Novel Broadly Expressed Tumor Antigen. (2006) (0)
Minimal residual disease in malignant melanoma after immunotherapy (1993) (0)
POS1271 PREVALENCE OF JOINT EFFUSION, HYPERPERFUSION AND ENTHESITIS IN YOUNG HEALTHY INDIVIDUALS (2021) (0)
Pulling the trigger on the tumor's bodyguards: what puts Tregs out of action? (2011) (0)
Nectin-4 is widely expressed in head and neck squamous cell carcinoma (2022) (0)
POS1387 ULTRASOUND FINDINGS OF JOINTS AND ENTHESES FOLLOWING ONE HOUR OF AGE AND GENDER ADJUSTED WEIGHT TRAINING (2022) (0)
Characterization of Gene p306 Expressed in Monocyte Derived Dendritic Cells (2008) (0)
Hospital sanitary facilities on wards with high antibiotic exposure play an important role in maintaining a reservoir of resistant pathogens, even over many years (2023) (0)
hDectin-1 Mediates Cross-Presentation of Epitopes Via the Cytosolic Pathway. (2007) (0)
Cotransfection of Dendritic Cells with RNA Coding for a Tumor Antigen and Costimulatory Molecule 4-1BBL Increases the Induction of Her-2/neu Specific Cytotoxic T-Cells. (2004) (0)
Impact of Donor Type on Outcome after Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia Patients: Analysis of the German-Austrian Acute Myeloid Leukemia Study Group (AMLSG) (2014) (0)
A Matched-pair Analysis on the Effect of Migration Background on Response Rates and Survival of Cancer Patients Treated at a Comprehensive Cancer Center in Germany (2020) (0)
Clinical Impact of TET2 Mutations in Acute Myeloid Leukemia Patients Harboring CEBPA Mutations: A Study of the AML Study Group (AMLSG) (2013) (0)
Lenalidomide versus bortezomib maintenance after frontline autologous stem cell transplantation for multiple myeloma (2021) (0)
Identification of RGS5 as a tumor-associated antigen expressed in a broad range of human malignancies and recognized by antigen specific cytotoxic T cells. (2006) (0)
BIOLUMA: Biomarkers for nivolumab and evaluation of nivolumab plus ipilimumab in lung cancer (2018) (0)
Quantification of unperturbed phosphoprotein levels in immune cell subsets with phosphoflow to assess immune signaling in autoimmune disease (2022) (0)
Periodontitis Lesions Activation of Invariant NK T Cells in (0)
Matrilysin ( MMP-7 ) Is a Novel Broadly ExpressedTumorAntigen Recognized byAntigen - (2008) (0)
EF 24 Suppresses Cholangiocellular Carcinoma Progression , Inhibits STAT 3 Phosphorylation , and Induces Apoptosis via ROS-Mediated Oxidative Stress (2019) (0)
Impact of cytogenetics at relapse on prognosis and benefit from salvage autologous stem cell transplantation in the GMMG phase III trial ReLApsE (2019) (0)
Regulation of Dendritic Cell Function by Histone Deacetylase Inhibitors. (2006) (0)
Interferon Gamma (IFNγ) Interferes with the Effects of Tyrosine Kinase Inhibitors (TKI) In CML Cells. (2010) (0)
A Predictive Score for Early Mortality during Induction Therapy in Newly Diagnosed Transplant-Eligible Multiple Myeloma - an Analysis from Five GMMG and HOVON Multicenter Phase III Trials (2017) (0)
Baseline immune signature score of Tregs × HLA-DR+CD4+ T cells × PD1+CD8+ T cells predicts outcome to immunotherapy in cancer patients (2022) (0)
Murine hematopoietic stem cell reconstitution potential is maintained by osteopontin during aging (2018) (0)
Muc-1 peptide antigen to trigger an immune reaction against tumor cells. (2000) (0)
The EMT regulator Zeb2 is essential for adult hematopoietic stem and progenitor cell differentiation (2012) (0)
Two cases of EBV infection preceding lymphoma (2022) (0)
Interaction of platelets with dendritic cells — Potential role for immunomodulatory processes in vascular remodelling (2006) (0)
P-177: Predictive factors for severe infections and early death during novel agent-based induction therapy in newly diagnosed, transplant-eligible myeloma: a multicohort analysis from phase III trials (2021) (0)
Outcome of Fungal Infection in Patients Undergoing Myelosuppressive Chemotherapy in a Tertiary Care Centre During 12 Years (1995-2006). (2009) (0)
Dendritic cellsImmunotherapy of malignant diseases with peptide pulsed dendritic cells (2001) (0)
Targeting Syk (spleen tyrosine kinase) Inhibits the Proliferation, Migration and Viability of Multiple Myeloma Cells (2010) (0)
Acknowledgement to Reviewers (2018) (0)
IL-2 based immunotherapy and chemo immunotherapy in melanoma (1993) (0)
[Imaging of eosinophilic fasciitis in ultrasound and MRI (magnetic resonance imaging): a case report]. (2022) (0)
Pretreatment prognostic parameters for response to immunotherapy with IFNαL-2 in metastatic melanoma (MM) (1993) (0)
Vascular expression of prostate-specific membrane antigen in renal tumors: Diagnostic and prognostic role (2018) (0)
Second-line and third-line therapy with nanoliposomal irinotecan (nal-IRI) in pancreatic cancer: a single-center experience and review of literature (2023) (0)
In vivo and In vitro Identification of Endocannabinoid Signaling in Periodontal Tissues and Their Potential Role in Local Pathophysiology (2017) (0)
AB0465 ANALYSIS OF VASCULITIS PATTERNS IN PATIENTS WITH GIANT CELL ARTERITIS COMPARED TO PATIENTS WITH GIANT CELL ARTERITIS AND POLYMYALGIA RHEUMATICA (2020) (0)
Peroxisome proliferator activated receptor γ (PPARγ) agonists for treatment of neoplastic diseases - in vitro data and early clinical observations in chronic myelomnocytic leukemia (CMML) and in liposarcoma (2001) (0)
AB0152 PROSPECTIVE ANALYSIS OF OBSTRUCTIVE SLEEP APNEA IN NEWLY DIAGNOSED PATIENTS WITH RHEUMATOID ARTHRITIS, PSORIATIC ARTHRITIS AND PERIPHERAL SPONDYLOARTHRITIS – A SCREENING STUDY (2021) (0)
T Cell Epitopes Reveals the Immunodominance of Presented Immunity Against Breast Carcinomas and Induces CD 4-and CD 8-Mediated T Cell Transfection of Dendritic Cells with RNA (2003) (0)
The role of autoimmunity and autoinflammation in giant cell arteritis: A systematic literature review. (2023) (0)
Imatinib Mesylate Induces BCR-ABL Independent Inhibition of Proteasomal Activity in CML Cells (2008) (0)
PF597 HIGH DOSE MELPHALAN (200MG/M2) AND AUTOLOGOUS TRANSPLANTATION IN NEWLY-DIAGNOSED MULTIPLE MYELOMA UP TO THE AGE OF 70 YEARS: A SUBGROUP ANALYSIS FROM THE PHASE III GMMG-MM5 TRIAL (2019) (0)
In the phase 3 IMmotion151 trial of metastatic renal cell carcinoma the easy-to-implement modified Glasgow prognostic score predicts outcome more accurately than the IMDC score. (2022) (0)
A matched-pair analysis on survival and response rates between German and non-German cancer patients treated at a Comprehensive Cancer Center (2019) (0)
Suppression of Interferon Regulatory Factor 8 Modulates Toll Like Receptor 2 and Toll Like Receptor 7/8 Induced Dendritic Cell Activation (2008) (0)
The Imatinib and Nilotinib Induced Modulation of the Proteasomal Activity and Antigen Processing in Chronic Myeloid Leukemia Cells (2011) (0)
Tumorvakzinierung ; Tumor immunization. On the way to individualized treatment (2012) (0)
Genetic Inhibition of PD-L1 on Myeloma Cells Improves Survival in Contrast to the Treatment with Checkpoint Inihibitors (2021) (0)
Characterization of Dendritic Cell-Specific Genes p275 and p306. (2006) (0)
840. Recombinant Sendai Virus Vectors with Matrix Protein Gene Deletion Restore Dendritic Cell Allostimulatory Activity (2005) (0)
BG-flow, a new flow cytometry tool for G-quadruplex quantification in fixed cells (2021) (0)
Transfection of Dendritic Cells with In Vitro Transcribed RNA Induces Polyclonal CMV-Specific CD8+ and CD4+ Mediated T Cell Responses. (2004) (0)
Antibiotic prophylaxis in AML: Comparison of ciprofloxacin and cotrimoxazole in 2 cohorts of patients who received AML induction chemotherapy (2013) (0)
Title Pages / Table of Contents (2011) (0)
[Progressive induration of the skin with rough papules]. (2017) (0)
Proteasome Inhibitors Affect the Function of Human Dendritic Cells and Induce Caspase-Mediated Apoptosis. (2005) (0)
1028P BIOLUMA: A phase II trial of nivolumab in combination with ipilimumab to evaluate efficacy and safety in lung cancer and to evaluate biomarkers predictive for response – results from the NSCLC cohort (2022) (0)
Early C-reactive protein kinetics predicts immunotherapy response in non-small cell lung cancer in the phase III OAK trial (2023) (0)
ErratumDendritic cells in vaccination therapies of malignant diseases: [Transfusion and Apheresis Science 2002;27:183–186] (2003) (0)
Contents, Vol. 16, 1993 (1983) (0)
The therapeutic use of dendritic cells transfected with tumour RNA (2005) (0)
POS1126 PREVALENCE OF HYPOPHOSPHATASIA IN ADULT RHEUMATOLOGY PATIENTS SCREENED BY LOW LEVELS OF ALKALINE PHOSPHATASE (2021) (0)
Generation of Immunosuppressive Antigen Presenting Cells with the Phenotype and Function of Myeloid Derived Suppressor Cells (2012) (0)
Specialized Dermatological - Rheumatological Patient Management Improves Diagnostic Outcome and Patient Journey: A Four-Year Analysis (2021) (0)
Editorial Board / Contents / Imprint (2018) (0)
Peroxisome Proliferator-Activated Receptor (PPAR)-Gamma Agonists Inhibit Dectin-1 mediated Activation of Human Dendritic Cells (DC). (2009) (0)
Phase II Study of Intermittent Low-Dose IFN-gamma in Metastatic Renal Cell Cancer (1993) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Peter Brossart?

Peter Brossart is affiliated with the following schools:

University of Tübingen
University of Genoa
University of Washington
University of Bonn